Press "Enter" to skip to content

Good news, @UniofOxford: Serum Institute CEO after Astrazeneca-Oxford resumes coronavirus vaccine trials in UK

After Astrazeneca-Oxford coronavirus vaccine resumed trials in the UK, Serum Institute of India (SII) on Saturday said it will resume trials in India once the Drugs Controller General of India (DCGI) grants it permission. Taking to Twitter, Serum Institute CEO Adar Poonawalla said, “As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford.”

Leave your comments

%d bloggers like this: